Current and future treatment options for nonexudative and exudative age-related macular degeneration

Drugs and Aging

Volumn 21, Issue 15, 2004, Pages 967-992

  Comer, Grant M ^a   Ciulla, Thomas A ^b   Criswell, Mark H ^a   Tolentino, Michael ^c,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MIDWEST EYE INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ALPHA TOCOPHEROL; ANECORTAVE; ANGIOGENESIS INHIBITOR; ANTIOXIDANT; ASCORBIC ACID; BENZOPORPHYRIN DERIVATIVE; BETA CAROTENE; CAND5; CELECOXIB; COMBRETASTATIN A4; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; ENVISION TD; FLUOCINOLONE ACETONIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIDOSTAURIN; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; POSURDEX; PRINOMASTAT; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; RANIBIZUMAB; RUBOXISTAURIN; SMALL INTERFERING RNA; SQUALAMINE; THALIDOMIDE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

AGING; ANGIOGENESIS; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; APHERESIS; ARGON LASER; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIET SUPPLEMENTATION; DIODE LASER; DROWSINESS; DRUG EFFICACY; DRUG IMPLANT; DRUG SAFETY; DRUSEN; ENZYME INHIBITION; HUMAN; HYPERTHERMIC THERAPY; INDOCYANINE GREEN ANGIOGRAPHY; LASER COAGULATION; META ANALYSIS; NONHUMAN; PERIPHERAL NEUROPATHY; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; TRANSPUPILLARY THERMOTHERAPY; TREATMENT OUTCOME; UVEA MELANOMA; VIRAL GENE THERAPY; VISUAL IMPAIRMENT;

AGED; AGING; EXUDATES AND TRANSUDATES; HUMANS; MACULAR DEGENERATION;

EID: 11444260529     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421150-00002     Document Type: Review

References (240)

1. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham eye study: I. Outline and major prevalence findings. Am J Epidemiol 1977; 106: 17-41
2. Attebo K, Mitchell P, Smith W. Visual acuity and the causes of visual loss in Australia: the Blue Mountains Eye Study. Ophthalmology 1996; 103: 357-64
3. Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam study. Arch Ophthalmol 1998; 116: 653-8
4. Tielsch JM, Javitt JC, Coleman A, et al. The prevalence of blindness and visual impairment among nursing home residents in Baltimore. N Engl J Med 1995; 332: 1205-9.
5. Seddon JM. Epidemiology of age-related macular degeneration. In: Ryan SJ, editor. Retina. St Louis (MO): Mosby, 2001: 1039-50
6. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol 1995; 39: 367-74
7. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol 1991; 109: 1109-14
8. Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch Ophthalmol 1993; 111: 1189-99
9. Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration. Arch Ophthalmol 1982; 100: 912-23
10. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: three-year results from randomized clinical trials. Arch Ophthalmol 1986; 104: 694-701
11. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol 1993; 115: 786-91
12. Moisseiev J, Alhalel A, Masuri R, et al. The impact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration. Arch Ophthalmol 1995; 113: 185-9
13. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 1417-36
14. Fliesler SJ, Anderson RE. Chemistry and metabolism of fluids in the vertebrate retina. Prog Lipid Res 1983; 22: 79-131
15. Gerster H. Review: antioxidant protection of the aging macula. Age Aging 1991; 112: 60-9
16. Young RW. Solar radiation and age-related macular degeneration. Surv Ophthalmol 1988; 32: 252-69
17. Beatty S, Koh H, Phil M, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000; 45: 115-34
18. Newsome DA, Swartz M, Leone NC, et al. Oral zinc in macular degeneration. Arch Ophthalmol 1988; 106: 192-8
19. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35
20. National Eye Institute. Complications of Age-Related Macular Degeneration Prevention Trial (CAPT) [online]. Available from URL: http://www.nei.nihgov/ neitrials/static/study70.htm [Accessed 2003 Sep 21]
21. PTAMD Clinical Trial [online]. Available from URL: http://www.iridex.com/ ophthalmology/ptamd_clinical_trial.html [Accessed 2004 Apr 27]
22. MIRA-1. (AMD) Age-Related Macular Degeneration Clinical Trials [online]. Available from URL: http://www.amd-study.com [Accessed 2004 Sep 28]
23. The Multicenter Investigation of Rheophoresis for AMD (MIRA-1) Study Group. Multicenter, prospective, randomized, double-masked, placebo-controlled study of rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans Am Ophthalmol Soc 2002; 100: 85-108
24. Nader N. Clinical trials show promise of intravitreal steroids, other therapies for retinal diseases. Ocular Surgery News 2004; 22 (3): 28-30
25. Bone RA, Landrum JT, Tarsis SL. Preliminary identification of the human macular pigment. Vision Res 1985; 25: 1531-5
26. Bone RA, Landrum JT, Hime GW, et al. Stereochemistry of the human macular pigment. Invest Ophthalmol Vis Sci 1993; 34: 2033-40
27. Malinow MR, Feeney-Burns L, Peterson LH, et al. Diet-related macular anomalies in monkeys. Invest Ophthalmol Vis Sci 1980; 19: 857-63
28. Neuringer M, Klein ML, Snodderly DM, et al. Effects of carotenoid depletion and N-3 fatty acid status on macular defects in Rhesus monkeys [abstract]. Invest Ophthalmol Vis Sci 1999; 40 (S164): 842
29. Ciulla TA, Curran-Celantano J, Cooper DA, et al. Macular pigment optical density in a midwestern sample. Ophthalmology 2001; 108: 730-7
30. Schalch W. Carotenoids in the retina: a review of their possible role to prevent or limit damage by light and oxygen. EXS 1992; 62: 280-98
31. Snodderly DM, Auran JD, Delori FC. The macular pigment: II. spatial distribution in primate retinas. Invest Ophthalmol VIPs Sci 1984; 25: 674-85
32. Katz ML, Parker KR, Handelman GJ, et al. Effects of antioxidant nutrient deficiency on the retina and retinal pigment epithelium of albino rats: a light and electron microscopic study. Exp Eye Res 1982; 34: 339-69
33. Seddon JM, Hennekens CH. Vitamins, minerals, and macular degeneration: promising but unproven hypotheses. Arch Ophthalmol 1994; 112: 176-8
34. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration: Eye Disease Case-Control Study Group. JAMA 1994; 272: 1413-20
35. West S, Vitale S, Hallfrisch J, et al. Antioxidants and supplements: protective for age-related macular degeneration. Arch Ophthalmol 1994; 112: 222-7
36. Gale CR, Hall NF, Phillips DI, et al. Lutein and zeaxanthin status and risk of age-related macular degeneration. Invest Ophthalmol Vis Sci 2003; 44: 2461-5
37. Hammond Jr BR, Ciulla TA, Snodderly DM. Macular pigment density is reduced in obese subjects. Invest Ophthalmol Vis Sci 2002; 43: 47-50
38. Seddon JM, Cote J, Davis N, et al. Progression of age-related macular degeneration association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol 2003; 121: 785-92
39. Mares-Perlman JA, Brandy WE, Klein R, et al. Serum antioxidants and age-related macular degeneration in a population-based case-control study. Arch Ophthalmol 1995; 113: 1518-23
40. Young RW. Pathophysiology of age-related macular degeneration. Surv Ophthalmol 1987; 31: 291-306
41. Eagle RJ. Mechanisms of maculopathy. Ophthalmology 1984; 91: 613-25
42. Green WR, McDonnell PJ, Yeo JH. Pathologic features of senile macular degeneration. Surv Ophthalmol 1985; 92: 615-27
43. Sarks SH. Ageing and degeneration in the macular region: a clinico-pathological study. Br J Ophthalmol 1976; 60: 324-41
44. Frennesson IC, Nelsson SE. Prophylactic laser treatment in early age-related maculopathy reduced the incidence of exudative complication. Br J Ophthalmol 1998; 82: 1169-74
45. Gass JD. Drusen and disciform macular detachment and degeneration. Arch Ophthalmol 1973; 90: 206-17
46. Wang JJ, Foran S, Smith W, et al. Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort. Arch Ophthalmol 2003; 121: 658-63
47. Ho AC, Maguire MG, Yoken J, et al. Laser induced drusen reduction improves visual function at 1 year. Ophthalmology 1999; 106: 1367-74
48. Olk RJ, Friberg TR, Stickney KL, et al. Therapeutic benefits of infrared (810nm) diode laser macular grid photocoagulation in prophylactic treatment of non-exudative age-related macular degeneration: two year results of a randomized pilot study. Ophthalmology 1999; 106: 2082-90
49. Ciulla TA, Harris A, Kagemann L, et al. Choroidal perfusion perturbations in non-neovascular age related macular degeneration. Br J Ophthalmol 2002; 86: 209-13
50. Ciulla TA, Harris A, Martin BJ. Ocular perfusion and age-related macular degeneration. Acta Ophthalmol Scand 2001; 79: 108-15
51. Ciulla TA, Harris A, Chung HS, et al. Color Doppler imaging discloses reduced ocular blood flow velocities in nonexudative age-related macular degeneration. Am J Ophthalmol 1999; 128: 75-80
52. Friedman E, Krupsky S, Lane AM, et al. Ocular blood flow velocity in age-related macular degeneration. Ophthalmology 1995; 102: 640-6
53. Friedman E. A hemodynamic model of the pathogenesis of age-related macular degeneration. Am J Ophthalmol 1997; 124: 677-82
54. Boker T, Fang T, Steinmetz R. Refractive error and choroidal perfusion characteristics in patients with choroidal neovascularization and age-related macular degeneration. Ger J Ophthalmol 1993; 2: 10-3
55. Remulla JF, Gaudio AR, Miller S, et al. Foveal electroretinograms and choroidal perfusion characteristics in fellow eyes of patients with unilateral neovascular age-related macular degeneration. Br J Ophthalmol 1995; 79: 558-61
56. Zhao J, Frambach DA, Lee PP, et al. Delayed macular choriocapillary circulation in age-related macular degeneration. Int Ophthalmol 1995; 19: 1-12
57. Widder RA, Brunner R, Engels B, et al. Changes of hemorheological and biochemical parameters after plasma perfusion using a tryptophan-polyvinyl alcohol adsorber leading to clinical improvement in patients suffering from maculopathy. Blood Purif 1998; 16: 15-21
58. Brunner R, Widder RA, Walter P, et al. Change in hemorrheological and biochemical parameters following membrane differential filtration. Int J Artif Organs 1995; 18: 794-8
59. Brunner R, Widder RA, Walter P, et al. Influence of membrane differential filtration on the natural course of age-related macular degeneration. Retina 2000; 20: 483-91
60. Boyer D, Gallemore R. Clinical trials assess rheopheresis [online]. Available from URL: http://www.mdsupport.org/library/rheotri2.html [Accessed 2003 Aug 10]
61. McGwin Jr G, Owsley C, Curcio CA, et al. The association between statin use and age related maculopathy. Br J Ophthalmol 2003; 87: 1121-5
62. Wilson HL, Schwartz DM, Bhatt HR, et al. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol 2004; 137: 615-24
63. Hall NF, Gale CR, Syddall H, et al. Risk of macular degeneration in users of statins: cross sectional study. BMJ 2001; 323: 375-6
64. McCarty CA, Mukesh BN, Guymer RH, et al. Cholesterol-lowering medications reduce the risk of age-related maculopathy progression [letter]. Med J Aust 2001; 175: 340
65. Klein R, Klein BE, Tomany SC, et al. Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch Ophthalmol 2003; 121: 1151-5
66. Macular Photocoagulation Study Group. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol 1986; 104: 503-12
67. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesion in age-related macular degeneration. Arch Ophthalmol 1991; 109: 1220-31
68. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration; guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 1991; 109: 1242-57
69. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Arch Ophthalmol 1993; 111: 1200-9
70. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials. TAP report. Arch Ophthalmol 1999; 117: 1329-45
71. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP report 2. Arch Ophthalmol 2001; 119: 198-207
72. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials. TAP report 5. Arch Ophthalmol 2002; 120: 1307-14
73. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-60
74. Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2002; 133: 168-9
75. QLT Inc. Occult AMD [online]. Available from URL: http://www.qltinc.com/ Qltinc/main/mainpages.cfm?.InternetPageID = 143 [Accessed 2004 Apr 29]
76. Centers for Medicare and Medicaid Services [online]. Available from URL: http://www.cms.hhs.gov [Accessed 2004 Apr 29]
77. Bressler NM, Rosenfeld PJ, Lim JI, et al. A phase II placebo-controlled, double-masked, randomized trial: Verteporfin in minimally classic CNV due to AMD (VIM) [abstract]. Invest Ophthalmol Vis Sci 2003; 44: E-abstract 1100
78. Gonzalez J. Visudyne benefits patients with minimally classic lesion at 1 year. Ocular Surgery News 2003; 21 (16): 40, 48
79. Rosenfeld PJ, VIM Study Group. Verteporfin in minimally classic CNV due to AMD (VIM): two-year results from a phase II controlled clinical trial [abstract]. Invest Ophthalmol Vis Sci 2004; 45: E-abstract 2273
80. Riddle J. PDT: therapies on the cutting edge. Rev Ophthalmology 2003; X (8): 40-6
81. LuEsther T. Mertz Retinal Research Center. Study compares early vs standard visudyne therapy for AMD [online]. Available from URL: http://www.retinal-research.org/study_descriptions.html#visudyne [Accessed 2003 Nov 10]
82. Stur M, VER Study Group. Verteporfin Early Retreatment (VER): 12-month results of a phase IIIB controlled clinical trial [abstract]. Invest Ophthalmol Vis Sci 2004; 45: E-abstract 2275
83. Slakter JS, Rosenfeld PJ, VALIO Study Group. Verteporfin with altered (delayed) light in occult CNV (VALIO): results of a phase II controlled clinical trial [abstract]. Invest Ophthalmol Vis Sci 2003; 44: E-abstract 1101
84. Singerman LJ, Rosenfeld PJ, VALIO Study Group. Verteporfin with altered (delayed) light in occult (VALIO): 12-month results of a phase II controlled clinical trial [abstract]. Invest Ophthalmol Vis Sci 2004; 45: E-abstract 2274
85. Peyman GA, Moshfeghi DM, Moshfeghi A, et al. Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2). Ophthalmic Surg Lasers 1997; 28: 409-17
86. Moshfeghi DM, Peyman GA, Moshfeghi A, et al. Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: time dependencies. Ophthalmic Surg Lasers 1998; 29: 663-8
87. Thomas EL, SnET2 Study Group. SnET2 photodynamic therapy for age-related macular degeneration: visual acuity efficacy outcomes from two parallel phase III trials [abstract]. Invest Ophthalmol Vis Sci 2004; 45: E-abstract 2214
88. Miravant Medical Technologies. SnET2 phase III clinical trials for wet age-related macular degeneration (wet AMD) [online]. Available from URL: http://www.miravant.com/Pages?.PhotoPoint_Center/Clin_Trials.htm [Accessed 2004 Apr 27]
89. Blumenkranz MS, Miller J, Guyer D, et al. Preliminary results from a phase II dose-response study of photodynamic therapy with motexafin lutetium to treat subfoveal CNV [abstract]. Invest Ophthalmol Vis Sci 2000; 41 (S531): 2827
90. TTT4CNV Clinical Trial [online]. Available from URL: http://www.optimed. com.au/TTT4CNV.htm [Accessed 2003 Aug 9]
91. Roach L. Macugen ups the anti-AMD ante. Eyenet 2004 Apr; 8: 29-30
92. Eyetech Pharmaceuticals Inc. Clinical trials [online]. Available from URL: http://www.eyetk.com/clinical/clinical_index.asp [Accessed 2003 Sep 25]
93. Clinical Trials.gov. Macular degeneration [online]. Available from URL: http://www.clinicaltrials.gov keyword = macular degeneration [Accessed 2004 Sep 25]
94. Acuity Pharmaceuticals [online]. Available from URL: www.acuitypharma.com [Accessed 2004 Apr 27]
95. Campochiaro PA, C99-PKC412-003 Study Group. Phase 2 study results of oral PKC412 in diabetic macular edema [abstract]. Invest Ophthalmol Vis Sci 2003; 44: E-abstract 4286
96. Eli Lilly Co. Key study findings about diabetic eye disease may lead to improved screenings and treatment for people with diabetes [online]. Available from URL: http://www.newsroom.lilly.com/news/Product/2004-09- 06_diabetic_retinopathy_dme-easd.html [Accessed 2004 Sep 28]
97. Rasmussen H, Chu KW, Campochiaro P, et al. Clinical protocol: an open-label, phase I, single administration dose-escalation study of ADovPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001; 12: 2029-32
98. GenVec Inc. PEDF program: a new approach to prevent blindness [online]. Available from URL: http://www.genvec.com/products_gene_therapy_pedf.asp [Accessed 2003 May 10]
99. ClinicalTrials.gov. Celecoxib to treat macular degeneration in patients receiving photodynamic therapy [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/NCT00043680?.order = 1 [Accessed 2003 Aug 10]
100. Genaera. Genaera reports squalamine continues to improve vision at four months timepoint in age-related macular degeneration [online]. Available from URL: http://www.genaera.com/pressreleases/2003_oct7.html [Accessed 2003 Nov 10]
101. Garcia C, Bartsch DU, Rivero ME, et al. Efficacy of prinomastat (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization. Curr Eye Res 2002; 24: 33-8
102. Maguire MG, Fine SL, Maguire AM, et al. Results of the Age-Related Macular Degeneration and Thalidomide Study (AMDATS) [abstract]. Invest Ophthalmol Vis Sci 2001; 42: 1255
103. Pharmacological Therapy for Macular Degeneration Study Group. Interferon Alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 1997; 115: 865-72
104. Penfold PL, Gyory JF, Hunyor AB, et al. Exudative macular degeneration and intravitreal triamcinolone: a pilot study. Aust N Z J Ophthalmol 1995; 23: 293-8
105. Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244-50
106. Ranson NT, Danis RP, Ciulla TA, et al. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularization after laser treatment in macular degeneration. Br J Ophthalmol 2002; 86: 527-9
107. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 1998; 26: 277-81
108. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration. Arch Ophthalmol 2003; 121: 667-73
109. Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br J Ophthalmol 2003; 87 (4): 462-8
110. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110: 1517-25
111. Charters L. More effective weapons available for fight against AMD. Ophthalmology Times 2003; 28 (23): 1, 14-5
112. The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesion in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 2003; 23: 14-23
113. Bausch & Lomb Inc. Bausch & Lomb and Control Delivery Systems announce results of first phase III clinical trial of Envision TD ophthalmic implant for treatment of diabetic macular edema [online]. Available from URL: http://www.bausch.com/us/vision/about/news/press-release.jsp?.pressRelease = pressrelease63.ea.html [Accessed 2003 May 10]
114. Control Delivery Systems Inc. Control Delivery Systems [online]. Available from URL: http://www.controldelivery.com. [Accessed 2004 Apr 27]
115. Oculex announces positive clinical results for Posurdes®: the first biodegradable ocular implant in clinical trial [online]. Available from URL: http://www.prnewswire.com/cgi-bin/micro_stories.pl?.ACCT=146549&TICK= OCLX&STORY=/www/story/05-08-2003/0001942910&EDATE=May+8,+2003 [Accessed 2003 May 10]
116. Marcus DM, Peskin E, Alexander J, et al. The age-related macular degeneration radiotherapy trial (AMDRT): 1 year results. Invest Ophthalmol Vis Sci 2003; 44: E-abstract 3158
117. National Institute of Health. Submacular surgery trials (SST) [online]. Available from URL: http://www.nei.nih.gov/neitrials/static/study52.htm [Accessed 2003 Sep 20]
118. Shiraga F, Ojima Y, Matsuo T, et al. Feeder vessel photocoagulation of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 1998; 105: 662-9
119. Sayag D, Coscas F, Coscas G, et al. Feeder vessel treatment with millipulse diode laser on occult subfoveal choroidal new vessels in age-related macular degeneration (AMD) using high speed ICG-angiography [abstract]. Invest Ophthalmol Vis Sci 2003; 44: E-abstract 1776
120. Roh M, Glaser B. Feeder vessel treatment of occult with no classic choroidal neovascularization in age-related macular degeneration. Invest Ophthalmol Vis Sci 2003; 44: E-abstract 1776
121. National Eye Institute. Identification and treatment of feeder vessels in macular degeneration [online]. Available from URL: http://www.clinicaltrials. gov/ct/show/NCT00018070?.order=2 [Accessed 2003 Aug 10]
122. Reichel E, Puliafito CA, Duker JS, et al. Indocyanine green dye-enhanced diode laser photocoagulation of poorly defined subfoveal choroidal neovascularization. Ophthalmic Surg 1994; 25: 195-201
123. Hope-Ross MW, Gibson JM, Chell PB, et al. Dye enhanced laser photocoagulation in the treatment of a peripapillary subretinal neovascular membrane. Acta Ophthalmol 1994; 72: 134-7
124. Moriarty AP. Indocyanine green enhanced diode laser photocoagulation of subretinal neovascular membranes [letter]. Br J Ophthalmol 1994; 1994: 238-9
125. Pharmacyclics Inc. Pharmacyclics regains rights to Optrin from Alcon [online]. Available from URL: http://www.pharmacyclics.com/webpage_templates/ tert.php3?.page_name=pr_1004643211 [Accessed 2003 Sep 24]
126. Mori K, Yoneya S, Ohta M, et al. Angiographic and histologic effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-L-aspartyl chlorin e6). Ophthalmology 1999; 106: 1384-91
127. Obana A, Gohto Y, Kaneda K, et al. Selective occlusion of choroidal neovascularization by photodynamic therapy with a water-soluble photosensitizer, ATX-S10. Lasers Surg Med 1999; 24: 209-22
128. Kliman GH, Puliafito CA, Grossman GA, et al. Retinal and choroidal vessel closure using phthalocyanine photodynamic therapy. Lasers Surg Med 1994; 15: 11-8
129. Ciulla TA, Harris A, Kagemann L, et al. Transpupillary thermotherapy for subfoveal occult choroidal neovascularization: effect on ocular perfusion. Invest Ophthalmol Vis Sci 2001; 42: 3337-40
130. Reichel E, Berrocal AM, Ip M, et al. Transpupillary thermotherapy of occult subfoveal neovascularization in patients with age-related macular degeneration. Ophthalmology 1999; 106: 1908-14
131. Algvere PV, Libert C, Lindgarde G, et al. Transpupillary thermotherapy of predominantly occult choroidal neovascularization in age-related macular degeneration with 12 months follow-up. Acta Ophthalmol Scand 2003; 81: 110-7
132. Thach AB, Sipperley JO, Dugel PU, et al. Large-spot size transpupillary thermotherapy for the treatment of occult choroidal neovascularization associated with age-related macular degeneration. Arch Ophthalmol 2003; 121: 817-20
133. Ishibashi T, Miki K, Sorgente N, et al. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985; 103: 708-11
134. Kvanta A. Expression and regulation of vascular endothelial growth factor in choroidal fibroblasts. Curr Eye Res 1995; 14: 1015-20
135. Amin R, Puklin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 1994; 35: 3178-88
136. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelia cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996; 37: 855-68
137. Reddy VM, Zamora RL, Kaplan HJ. Distribution of growth factors in subfoveal neovascular membranes in age-related macular degeneration and presumed ocular histoplasmosis syndrome. Am J Ophthalmol 1995; 120: 291-301
138. Yi X, Ogata N, Komada M, et al. Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefes Arch Clin Exp Ophthalmol 1997; 235: 313-9
139. Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 1997; 151: 281-91
140. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114: 66-71
141. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995; 92: 10457-61
142. The Eyetech Study Group. Preclinical and phase IA clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002; 22: 143-52
143. The Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003; 110: 979-86
144. Heier JS, Sy JR, McCluskey ER, et al. RhuFab V2 in wet AMD: 6 month continued improvement following multiple intravitreal injections [abstract]. Invest Ophthalmol Vis Sci 2003; 44: E-abstract 972
145. Genentech Inc. Genentech announces preliminary positive phase Ib/II data for rhuFab V2 in age-related macular degeneration [online]. Available from URL: http://www.macular.org/news/clinical/rhufab.html [Accessed 2003 Sep 25]
146. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210-6
147. Tolentino MJ, Brucker AJ, Fosnot J, et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in nonhuman primate, laser-induced model of choroidal neovascularization. Retina 2004; 24: 132-8
148. Danis RP, Bingaman DP, Yang Y, et al. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996; 103: 2099-104
149. Kwak N, Okamoto N, Wood JM, et al. VEFG is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000; 41: 3158-64
150. Fabbro D, Ruetz S, Bodis S, et al. PKC412: a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000; 15: 17-28
151. Saishin Y, Silva RL, Saishin Y, et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci 2003; 44: 4989-93
152. Holekamp NM, Bouck N, Volpert O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol 2002; 134: 220-7
153. Takita H, Yoneya S, Gehlback PL, et al. Retinal neuroprotection against ischemic injury mediated by intraocular gene transfer of pigment epithelium derived factor. Invest Ophthalmol Vis Sci 2003; 44: 4497-504
154. Stellmach V, Crawford SE, Zhou W, et al. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 2001; 98: 2593-7
155. Mori K, Duh E, Gehlback P, et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Invest 2001; 188: 253-63
156. Leahy KM, Ornberg RL, Wang Y, et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002; 62: 625-31
157. Genaidy M, Kazi AA, Peyman GA, et al. Effect of squalamine on iris neovascularization in monkeys. Retina 2002; 22: 772-8
158. Higgins RD, Sanders RJ, Yan Y, et al. Squalamine improves retinal neovascularization. Invest Ophthalmol Vis Sci 2000; 41: 1507-12
159. Ciulla TA, Criswell MH, Danis RP, et al. Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina 2003 Dec; 23 (6): 808-14
160. D'Amore PA. Mechanisms of endothelial growth control. Am J Respir Cell Mol Biol 1992; 6: 1-8
161. Bischoff J. Approaches to studying cell adhesion molecules in angiogenesis. Trends Cell Biol 1995; 5: 69-74
162. Woesnner Jr JF. The matrix metalloproteinase family. In: Parks WC, Mecham RP, editors. Matrix metalloproteinases. San Diego (CA): Academy Press, 1998: 1-14
163. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling: review. Trends Genet 1990; 6: 121-5
164. Anand-Apte B, Pepper MS, Voest E, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci 1997; 38: 817-23
165. Steen B, Sejersen S, Berglin L, et al. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1998; 39: 2194-200
166. Fariss RN, Apte SS, Olsen BR, et al. Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye. Am J Pathol 1997; 150: 323-8
167. Kamei M, Holleyfield J. TIMP-3 in Bruch's membrane: change during aging and in age-related macular degeneration. Invest Ophthalmol Vis Sci 1999; 40: 2367-75
168. Ozerdem U, Mach-Hofacre B, Varki N, et al. The effect of prinomastat (AG2240), a synthetic inhibitor of matrix metalloproteinases, on uveal melanoma rabbit model. Curr Eye Res 2002; 24: 86-91
169. Ozerdem U, Mach-Hofacre B, Keefe K, et al. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy. Ophthalmic Res 2001; 33: 20-3
170. Cheng L, Rivero ME, Garcia CR, et al. Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit. J Ocular Pharm Ther 2001; 17: 295-304
171. Zhang KE, McDermott CK, Brekken J, et al. Ocular bioavailability and pharmacokinetics of AG3340, a potent MMP inhibitor with antiangiogenic activity, following oral administration. Tampa (FL): Proc New York Acad Science, 1998
172. Collier MA, Yuen BJ, Bansal SK, et al. Phase I study of the matrix metalloprotease inhibitor AG3340 given in a single dose to healthy volunteers. Proc Am Assoc Cancer Res 1997; 38: A1491
173. Nambu H, Nambu R, Melia M, et al. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 3650-5
174. D'Amato R, Loughnan M, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-5
175. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse model of neovascularization. Exp Eye Res 1997; 64: 971-8
176. Kruse FE, Joussen AM, Rohrschneider K, et al. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998; 236: 461-6
177. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980; 208: 516-8
178. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987; 47: 5151-61
179. White CW, Sondheimer HM, Crouch EC, et al. Treatment of pulmonary hemangiomatosis with recombinant interferon alpha-2a. N Engl J Med 1989; 320:
180. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alpha-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456-63
181. Fung WE. Interferon alpha 2a for treatment of age-related macular degeneration. Am J Ophthalmol 1991; 112: 349-50
182. Engler C, Sander B, Villumsen J, et al. Interferon alpha 2a modifies the course of subfoveal and juxtafoveal choroidal neovascularization. Br J Ophthalmol 1994; 78: 749-53
183. Chan CK, Kempin SJ, Noble SK, et al. The treatment of choroidal neovascular membranes by alpha interferon: an efficacy and toxicity study. Ophthalmology 1994; 101: 289-300
184. Miller JW, Stinson WG, Folkman J. Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology 1993; 100: 9-14
185. Jaakkola A, Anttila PM, Innonen I. Interferon alpha-2a in the treatment of exudative senile macular degeneration. Acta Ophthalmol (Copenh) 1994; 72: 545-9
186. Thoelen A, Menozzi M, Huber C, et al. Treatment of choroidal neovascularization in age-related macular degeneration with interferon alpha-2a: a short term, nonrandomized pilot study. Ger J Ophthalmol 1995; 4: 137-43
187. Thomas MA, Ibanez HE. Interferon alfa-2a in the treatment of subfoveal choroidal neovascularization. Am J Ophthalmol 1993; 115: 563-8
188. Folkman J, Ingber DE. Angiostatic steroids: method of discovery and mechanism of action. Ann Surg 1987; 206: 374-82
189. Ohkuma H, Ryan SJ. Vascular casts of experimental subretinal neovascularization in monkeys. Invest Ophthalmol Vis Sci 1983; 24: 481-90
190. Schlaegel TF. Ocular histoplasmosis. New York: Grund & Stratton, 1977
191. Martidis A, Miller DG, Ciulla TA, et al. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocul Pharmacol Ther 1999; 15: 425-8
192. Ciulla TA, Criswell MH, Danis RP, et al. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001; 119: 399-404
193. Jonas JB, Kreissig I, Degenring RF. Intraocular pressure after intravitreal injection of triamcinolone acetone. Br J Ophthalmol 2003; 87: 24-7
194. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or heparin fragment. Science 1995; 230: 1375-8
195. Clark AF. AL-3789: a novel ophthalmic angiostatic steroid. Exp Opin Invest Drugs 1997; 6: 1867-77
196. McNatt LG, Weimer L, Yanni J, et al. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther 1999; 15: 413-23
197. Clark AF, Mellon J, Li XY, et al. Inhibition of intraocular tumor growth by topical application of the antiangiogenic steroid anecortave acetate. Invest Ophthalmol Vis Sci 1999; 40: 2158-62
198. Penn JS, Rajaratnam VS, Collier RJ, et al. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001; 42: 283-90
199. The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy treatment of subfoveal neovascularization in age-related macular degeneration - twelve month clinical outcomes. Ophthmalogy 2003; 110: 2372-2383
200. Ho AC. Anecortave acetate: treatment for age-related macular degeneration [online]. Available from URL: http://www.retinalphysician.com/article.aspx? article=100005 [Accessed 2004 Sept 28]
201. Ciulla TA, Criswell MH, Danis RP, et al. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br J Ophthalmol 2003; 87: 1032-7
202. Yang CS, Khawly JA, Hainsworth DP, et al. An intravitreal sustained release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 1998; 116: 69-77
203. Perkins SL, Gallemore RP, Yang CH, et al. Pharmacokinetics of the fluorcinolon/5-fluorouracil codrug in the gas-filled eye. Retina 2000; 20: 514-9
204. Finger PT, Berson A, Sherr D. Radiation therapy for subretinal neovascularization. Ophthalmology 1996; 103: 878-89
205. Finger PT, Berson A, Ng T, et al. Ophthalmic plaque radiotherapy for age-related macular degeneration associated with subretinal neovascularization. Am J Ophthalmol 1999; 127: 170-7
206. Yonemoto LT, Slater JD, Friedrichsen EJ, et al. Phase I/II study of proton beam irradiation for the treatment of subfoveal choroidal neovascularization in age-related macular degeneration: treatment techniques and preliminary results. Int J Radiat Oncol Biol Phys 1996; 36: 867-71
207. Ciulla TA, Danis RP, Klein SB, et al. Proton therapy for exudative age-related macular degeneration: a randomized, sham-controlled clinical trial. Am J Ophthalmol 2002; 134: 905-6
208. Spaide RF, Guyer DR, McCormick B, et al. External beam radiation therapy for choroidal neovascularization. Ophthalmology 1998 Jan;105 (1): 24-30
209. Spaide RF. External beam radiation therapy for choroidal neovascularization. Ophthalmology 1998; 105: 24-30
210. Prettenhöfer U, Hass A, Mayer R, et al. Ther photon therapy of subfoveal choroidal neovascularization in age-dependent macular degeneration: the results of a prospective study in 40 patients. Strahlenther Onkol 1998; 12: 613-7
211. Roesen B, Scheider A, Kiraly A, et al. Choroidal neovascularization in senile macular degeneration. 1 year follow-up after radiotherapy. Ophthalmologe 1998; 95: 461-5
212. Char DH, Irvine AI, Posner MD, et al. Randomized trial of radiation for age-related macular degeneration. Am J Ophthalmol 1999; 127: 574-8
213. Anders N, Stahl H, Dorn A, et al. Radiotherapy of exudative senile macular degeneration: a prospective controlled study. Ophthalmologe 1998; 95: 760-4
214. Subasi M, Akmansu M, Or M. Treatment of age-related subfoveal neovascular membranes by teletherapy: results of a non-randomized study. Radiat Med 1999; 17: 169-73
215. Staar S, Krott R, Mueller RP, et al. External beam radiotherapy for subretinal neovascularization in age-related macular degeneration: Is this treatment effective? Int J Radiat Oncol Biol Phys 1999; 45: 467-73
216. Mauget-Faysse M, Chiquet C, Milea D, et al. Long term results of radiotherapy for subfoveal choroidal neovascularization in age related macular degeneration. Br J Ophthalmol 1999; 83: 923-8
217. Krott R, Staar S, Mueller RP, et al. External beam radiation in patients suffering from exudative age-related macular degeneration: a matched-pairs study and 1-year clinical follow-up. Graefes Arch Clin Exp Ophthalmol 1998; 236: 916-21
218. Sasai K, Murata R, Mandai M, et al. Radiation therapy for ocular choroidal neovascularization (phase I/II study): preliminary report. Int J Radiat Oncol Biol Phys 1997; 39: 173-8
219. Tholen AM, Meister A, Bernasconi PP, et al. Radiotherapy for choroidal neovascularization in age-related macular degeneration: a pilot study using low-versus high-dose photon beam therapy. Ophthalmologe 1998; 95: 691-8
220. Donati G, Soubrane D, Quaranta M, et al. Radiotherapy for isolated occult subfoveal neovascularization in age related macular degeneration: a pilot study. Br J Ophthalmol 1999; 83: 646-51
221. Weinberger AW, Wolf S, Kube T, et al. Radiation therapy of occult choroidal neovascularization in age-related macular degeneration. Klin Monatsbl Augenheilkd 1999; 214: 96-9
222. The Radiation Therapy for Age-related Macular Degeneration (RAD) Study Group. A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). Ophthalmology 1999; 106: 2239-47
223. Marcus DM, Sheils WC, Johnson MH, et al. External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double masked, randomized clinical trial. Arch Ophthalmol 2001; 119: 171-80
224. Bergink GJ, Hoyng CB, van der Maazen RW, et al. A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation. Graefes Arch Clin Exp Ophthalmol 1998; 236: 321-5
225. Thomas MA, Dickinson JD, Melberg NS, et al. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology 1994; 101: 1384-96
226. Gass JD. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol 1994; 118: 285-98
227. Lambert HM, Capone Jr A, Aaberg TM, et al. Surgical excision of subfoveal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1992; 113: 257-62
228. Mandelcorn MS, Menezes AV. Surgical removal of subretinal hemorrhage and choroidal neovascular membranes in acute hemorrhagic age-related macular degeneration. Can J Ophthalmol 1993; 28: 19-23
229. Ormerod LD, Puklin JE, Frank RN. Long-term outcomes after the surgical removal of advanced subfoveal neovascular membranes in age-related macular degeneration. Ophthalmology 1994; 101: 1201-10
230. Heimann K. A breakthrough in surgery for age-related macular degeneration? Graefes Arch Clin Exp Ophthalmol 1994; 232: 706
231. Hudson HL, Frambach DA, Lopez PF. Relation of the functional and structural fundus changes after submacular surgery for neovascular age-related macular degeneration. Br J Ophthalmol 1995; 79: 417-23
232. Del Priore LV, Kaplan HJ, Hornbeck R, et al. Retinal pigment epithelial debridement as a model for the pathogenesis and treatment of macular degeneration. Am J Ophthalmol 1996; 122: 629-43
233. Machemer R, Steinhorst UH. Retinal separation, retinotomy, and macular relocation: a surgical approach for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1993; 231: 635-41
234. de Juan Jr E, Loewenstein A, Bressler NM, et al. Translocation of the retina for management of subfoveal choroidal neovascularization II: a preliminary report in humans. Am J Ophthalmol 1998; 125: 635-46
235. Lewis H, Kaiser PK, Lewis S, et al. Macular translocation for subfoveal choroidal neovascularization in age-related macular degeneration: a prospective study. Am J Ophthalmol 1999; 128: 135-46
236. Algvere PV, Berglin L, Gouras P, et al. Transplantation of fetal retinal pigment epithelium in age-related macular degeneration with subfoveal neovascularization. Graefes Arch Clin Exp Ophthalmol 1994; 232: 707-16
237. Algvere PV, Berglin L, Gouras P, et al. Transplantation of RPE in age-related macular degeneration: observations in disciform lesions and dry RPE atrophy. Graefes Arch Clin Exp Ophthalmol 1997; 235: 149-58
238. Algvere PV. Clinical possibilities in retinal pigment epithelial transplantations. Acta Ophthalmol Scand 1997; 75: 1
239. Gouras P, Algvere PV. Retinal cell transplantation in the macula: new techniques. Vision Res 1996; 36: 4121-5
240. Little CW, Castillo B, DiLoreto DA, et al. Transplantation of human fetal retinal pigment epithelium rescues photoreceptor cells from degeneration in the Royal College of Surgeons rat retina. Invest Ophthalmol Vis Sci 1996; 37: 204-11